About Us

About Qing Mei Wang, MD, PhD

Qing Mei Wang, MD, PhD is a physiatrist who specializes in the care of patients with stroke. Dr. Wang obtained her PhD and MD at the University of Medicine and Dentistry of New Jersey and completed her residency training in Physical Medicine and Rehabilitation at Mount Sinai Medical Center in New York. After completing her residency training in 2008, Dr. Wang joined the faculty at Spaulding Rehabilitation Hospital (SRH), Massachusetts General Hospital (MGH), and Harvard Medical School (HMS), where she provides clinical care, supervises trainees, and conducts research on stroke recovery to enhance our knowledge and the quality of patient care. 

Dr. Wang’s research interests and expertise revolve around the mechanisms and interventions to promote stroke recovery. Since 2008, Dr. Wang has received funding from the NIH (e.g., K12 grant and K08) as well as departmental grants and international collaboration grant that aim to determine molecular biological mechanisms of stroke recovery and to develop pharmacological and non-pharmacological interventions. Dr. Wang is the director of the Stroke Biological Recovery Laboratory at Spaulding Rehabilitation Hospital.

Dr. Wang has presented her work at national and international conferences, and has more than 30 publications in peer-reviewed journals. She also works closely with the Spaulding team to translate cutting-edge stroke research into clinical care, such as integrating transcranial direct current stimulation into inpatient and outpatient stroke care.

Dr. Wang has been actively involved in teaching and supervising research fellows and residents since joining the Spaulding Rehabilitation Hospital/Massachusetts General Hospital/Harvard Medical School faculty. Some of Dr. Wang’s trainees are now independent investigators in China.

In addition to conducting research and teaching, Dr. Wang has been actively involved in clinical work, providing treatment for patients afflicted with stroke. She receives referrals from colleagues locally and regionally.  

About the Stroke Biological Recovery Laboratory

There are several areas of investigation that are critical to the Stroke Biological Recovery Laboratory’s core mission:

1. Develop novel interventions to promote stroke recovery. Our studies show promising results of two novel combination therapies (a. combined atorvastatin and sildenafil; b. combined transcranial direct current stimulation and methylphenidate) for improving motor recovery after stroke. We strive to improve the efficacy of these combination therapies and continue to develop new regimens.
2. Understand the role of inflammation in stroke recovery. We use serum and primary immune cells from stroke subjects, as well as rodent stroke models, to understand the role of inflammation in stroke recovery. Our data show derangement in inflammatory pathway in post-stroke fatigue. Further identification of the key players will provide new insight to develop therapeutic interventions.
3. Discover biomarkers to predict recovery and to serve as surrogate to evaluate the responsiveness to therapy for developing individualized therapy. We have been building bio-bank database including functional outcomes, serum sample and DNA. We also conduct biomarker sub-study in clinical trial.